Alcon says its newest dry eye drug can show improved tear production as early as day 1 of therapy, overcoming a key complaint about some interventions that require a ramp-up period.

Tryptyr (pronounced trip-tir), released by Alcon activates trigeminal nerve signaling, leading to increased basal tear production. The recommended dosing of Tryptyr is twice per day. 

Roughly half of subjects receiving the test drug met the primary outcome of at least a 10mm increase in Schirmer score at day 14, up to a fourfold increase over controls treated with the vehicle only, 

The Alcon press release also states that some subjects treated with Tryptyr demonstrated statistically significant natural tear production as early as day 1. The company anticipates a US launch in the third quarter of 2025. Tryptyr will be supplied in preservative-free, single-use vials.